Adverse reaction reporting in New Zealand (2020) On 22 April 2021, Med Safe published 2020-year Adverse reaction reporting statistics in New Zealand. […]
Blog Archive
0
Increased risk of angioedema with vildagliptin and ACE inhibitors
Increased risk of angioedema with vildagliptin and ACE inhibitors In March 2021, Medsafe, the New Zealand Medicines and Medical Devices Safety Authority […]
0
Designated Medical Event (DME)
Designated Medical Event (DME) European Medicines Agency has developed the Designated Medical Event (DME) list to help to prioritize the review of […]
0
South African Health Products Regulatory Authority Launches the Med Safety App for Self Reporting
South African Health Products Regulatory Authority Launches the Med Safety App for Self Reporting On 22 Apr 2021, South African Health Products […]
0
Safety signal (risk of thrombosis in combination with thrombocytopenia) VAXZEVRIA/COVID-19 Vaccine
Safety signal (risk of thrombosis in combination with thrombocytopenia) VAXZEVRIA/COVID-19 Vaccine European Medicines Agency EMA) has published Direct healthcare professional communications (DHPC) […]
1
Remdesivir Safety Profile
Remdesivir Safety Profile Remdesivir authorized in the EU as Veklury Remdesivir is an antiviral medicine used to treat coronavirus disease 2019 (COVID-19). […]
